This agreement provides every State Medicaid program access to MFN drug prices on new Regeneron products, Regeneron has also reduce the price of its cholesterol medicine, Praluent, from $537 to $225, and their new gene therapy for a rare type of genetic deafness, called Otarmeni, will be given to U.S. patients at no cost as part of this agreement.